Halozyme Therapeutics (HALO) Tops Q4 EPS by 11c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $113.76 -1.19%
Revenue Growth %: +36.2%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +36.2%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.03, $0.11 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $52.2 million versus the consensus estimate of $42.06 million.
GUIDANCE:
Halozyme Therapeutics sees FY2016 revenue of $110-125 million, versus the consensus of $120.2 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst
- AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
